Successful Autologous Peripheral Blood Stem Cell Transplantation Using Thiotepa in a Patient with Systemic Sclerosis and Cardiac Involvement

Abstract

A 19-year-old man with systemic sclerosis (SSc) was hospitalized for autologous peripheral blood stem cell transplantation (auto-PBSCT) due to progressive scleroderma and cardiac involvement despite conventional treatment. During the administration of cyclophosphamide (60 mg/kg/day for 2 days) for mobilization and collection of CD34 + selected peripheral blood stem cells, he developed congestive heart failure. Echocardiogram showed hypokinetic asynergy from the septum to posterior wall, which might indicate underlying cardiac damage. We were also concerned about the risk of high-dose cyclophosphamide-induced cardiotoxicity. Since the dose-limiting toxicity of thiotepa, an alkylating agent, is myelosuppression, and cardiac toxicity due to thiotepa is less common, we used a conditioning regimen consisting of thiotepa (10 mg/kg/day, day -5) and lowdose cyclophosphamide (50 mg/kg/day, days -3 and -2), instead of the conventional highdose cyclophosphamide (50 mg/kg/day × 4 days/course). The post-transplant course was uneventful, and the modified Rodnan skin thickness score improved from 32 to 15. The present case report demonstrates that thiotepa can be employed as a conditioning regimen for auto-PBSCT in SSc patients with cardiac involvement in order to reduce cyclophosphamide-induced cardiotoxicity.autologous peripheral blood stem cell transplantation (PBSCT); cardiotoxicity; cyclophosphamide; systemic sclerosis; thiotepa

Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature

“…). Nine additional studies were identified by manual searching . We first removed 119 duplicates and then screened the abstracts before excluding an additional 226 studies because of irrelevance.…”

Guidelines of the Brazilian Society of Bone Marrow Transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis

“…Komatsuda et al described HSCT applied to a patient with cardiac involvement using thiotepa and cyclophosphamide in small doses (100 mg/kg) as a conditioning regimen. There was no toxicity during transplantation and the patient was in disease remission (33) .…”

Consenso brasileiro para transplante de células-tronco hematopoéticas para tratamento de doenças autoimunes

“…Não houve toxicidade durante o transplante e o paciente obteve remissão da doença. 22 Como avaliar a função cardíaca do paciente com esclerose sistêmica?…”